HIV Scientific Papers
Comparable efficacy of ibalizumab in combination with 1 or 2 fully active agents.
2020
DeJesus E, McGary C, Mesquita P, et al.
Poster #507 presented at: Conference on Retroviruses and Opportunistic Infections; March 8-11, 2020; Boston, Massachusetts, USA.
Treatment with growth hormone releasing hormone analog reduces VEGF-A, TGFfβ-1, and CSF-1: Mechanisms of tesamorelin effect in nonalcoholic fatty liver disease [abstract].
2020
Hepatology.
Stanley TL, Fourman LT, Billingsley JM, et al.
72(suppl 1):142. Proceedings of The Liver Meeting (AASLD) 2020.
Treatment with growth hormone releasing hormone analog reduces VEGF-A, TGFfβ-1, and CSF-1: Mechanisms of tesamorelin effect in nonalcoholic fatty liver disease.
2020
Fourman LT.
Oral presentation #142 at: Annual Meeting of the American Association for the Study of Liver Diseases (The Liver Meeting); November 13-16, 2020; virtual.
Effect of tesamorelin on risk of development or progression of diabetic retinopathy and glycemic control in HIV-infected subjects with diabetes and central adiposity [abstract].
2020
Antiviral Therapy.
Brown TT, Bedimo R, Goss OG, et al.
25(suppl 1):A17. Proceedings of the 22nd International Workshop on Co-morbidities and Adverse Drug Reactions in HIV.
Effect of tesamorelin on risk of development or progression of diabetic retinopathy and glycemic control in HIV-infected subjects with diabetes and central adiposity.
2020
Brown TT, Bedimo R, Goss OG, et al.
Oral presentation at: 22nd International Workshop on Co-morbidities and Adverse Drug Reactions in HIV; November 30-December 4 2020; virtual.